Sekisui XenoTech Hiring and Growing to Meet Customer Demand

For over 20 years, Sekisui XenoTech has been known for its dedication to sound science, expert guidance and support in helping customers obtain data that meets or exceeds regulatory agency expectations when developing new therapeutics.

The company hired a record number of new staff over the past year in order to meet current demand for its products and services, which are utilized to optimize the discovery, development, and approval of new drugs and other compounds. Several previous Sekisui XenoTech employees also returned to the company. The new staff span Sekisui XenoTech’s contract research, quality assurance, business, IT, and other departments.

“Our hiring efforts are a reflection of our commitment to maintaining strict quality standards while meeting client needs and timelines,” explained Toshinari Ohara, PhD, CEO of Sekisui XenoTech. He added, “2017 ties 2011 for our second-highest number of new hires in a single year.”

One of the new additions was industry veteran Darren Warren, PhD, who became the company’s new COO in October. Upon joining Sekisui XenoTech, Dr. Warren noted, “I am excited to become a member of an organization with the distinguished performance history, leadership team strength, depth of scientific expertise, and position of market leadership that Sekisui XenoTech enjoys, and that holds an optimistic outlook towards future growth while maintaining commitment to excellence in providing a positive customer experience as well as outstanding contract services and products.”

In addition to growth, the company has made other internal changes. Dr. Ohara commented, “While hiring talent from outside the organization has many positive effects, such as introducing new ideas and expertise, we have also been focused on ongoing training and career advancement for our existent staff.” Sekisui XenoTech awarded numerous promotions to its staff this year, which prominently included elevating Joanna Barbara, PhD, to the position of Vice President of Scientific Operations and Brian Ogilvie, PhD, to the position of Vice President of Scientific Consulting. Joanna and Brian share a combined 30 years of experience with the company.

RELATED ARTICLES

A new AI method developed by Finnish researchers now provides answers about treatment effectiveness. Using modelling, the method makes it possible to compare different treatment alternatives and to identify patients who will benefit from treatment.

Despite decades of research, treatments that can target a common mutation in the most frequently diagnosed type of pancreatic cancer have remained elusive. Now, researchers report they have discovered a mechanism of resistance to a treatment they’d identified as promising.

Patients with human papillomavirus (HPV)-positive throat cancer should carry on receiving chemotherapy rather than switching to a targeted cancer drug during curative radiotherapy, new clinical trial results have shown.